TKI258

TKI258, also known as foretinib, is an orally active, multi-kinase inhibitor that targets various receptor tyrosine kinases, including c-Met, VEGFRs, PDGFRs, and FGFRs. It was developed by Novartis and was investigated for its potential in treating several types of cancer. Its mechanism of action involves blocking the signaling pathways that are crucial for tumor growth, proliferation, angiogenesis, and metastasis.

Clinical trials explored TKI258's efficacy in cancers such as advanced gastric cancer, papillary renal cell carcinoma, and non-small cell lung cancer. In gastric cancer, it was evaluated in combination with other chemotherapies. Studies aimed to assess its ability to improve progression-free survival and overall survival. While TKI258 demonstrated some anti-tumor activity, its development faced challenges, and it did not ultimately receive regulatory approval for widespread clinical use. Research into TKI258 has contributed to a broader understanding of multi-kinase inhibition in oncology and the complexities of targeting multiple signaling pathways simultaneously in cancer treatment.